Application: Controlling for non-heparan CBD-FGFbinding activity

Heparan Degrading Enzyme Assay Kit (Cat.# MK412)

The Heparan Degrading Enzyme Assay Kit employs a domain-oriented capture (DOC) method to detect the binding of undegraded heparan sulfate to the cell-binding domain of fibroblast growth factor (CBD-FGF) immobilized on the assay plate. If samples contain factors other than undegraded heparan that bind tightly to CBD-FGF, these factors may interfere with CBD-FGF binding to undegraded biotinylated heparan sulfate and hence reduce color development and assay read-out.

Therefore, to maintain accuracy it is necessary to confirm whether CBD-FGF binding activity not due to heparan is present in the assay system (for comparison, see list below of substances known to interact or not interact with FGF). The presence of this non-heparan CBD-FGF binding activity can be confirmed as follows:

- 1. In the absence of the biological sample (cell or tissue extract), incubate biotinylated heparan sulfate with and without the substance to be tested.
- Transfer the two reactions into the wells of a microtiter plate containing immobilized CBD-FGF and determine the levels of color development.
- 3. If the two test reactions produce the same level of color development, no inhibiting activity is present. If the reaction with the test substance is lower than the heparanonly control, the substance binds to CBD-FGF.

Alternatively, by utilizing this ability to detect inhibition of heparan binding, the kit can be used to screen for and study substances that have FGF-binding affinity. The following is a list of substances that Takara has confirmed to bind or not bind with FGF using this kit.

Interaction with FGF


Substances That Interact Dextran sulfate Chondroitin sulfate B Carrageenan lota, κ , λ

That Do Not Interact Chondroitin sulfate A

Chondroitin sulfate C Chondroitin sulfate D Keratan sulfate Pullulan Galactan Suramin

Assay Example

The levels of heparan sulfate degrading enzyme activity in various cultured cell extracts were measured using the Heparan Degrading Enzyme Assay Kit. Each cell sample $(5 \times 10^6$ cells) was processed with 1 ml of Extraction Buffer and then diluted with reaction buffer prior to being assayed. The level of enzyme activity correlates with the extent to which the absorbance level of the sample is decreased relative to the negative control.



Change in absorbance relative to control

LoVo: SW620: MES-SA: IMR32: MDAMB453: MCF7: Lu65: HL60: KATOIII: NUGC4: MKN74: MKN45: MKN1: A431: B16BL6:	human colon adenocarcinoma human colon adenocarcinoma human uterus sarcoma human neuroblastoma human breast cancer human breast cancer human lung carcinoma human gastric carcinoma
B16BL6:	mouse melanoma
10% FCS/RPMI:	negative control

TakaRa

TAKARA BIO INC. 800-662-2566 Notice to Purchaser. Your use of these products and technologies is subject to compliance with any applicable licensing requirements described on the product's web page at http://www.clontech.com/takara. It is your responsibility to review, understand and adhere to any restrictions imposed by such statements. The Takara logo is a trademark of TAKARA HOLDINGS, Kyoto, Japan. All other marks are the property of their respective owners. Certain trademarks may not be registered in all jurisdictions.